Posted by: Audrey Erbes | November 14, 2007

Pfizer makes nice with Nektar

It’s not surprising that Pfizer has settled with nice package of $135 million for withdrawing from the Exubera contract. (See details of settlement at ) Pfizer is rightfully concerned about losing its status as a “preferred partner” for potential future lucrative licensing deals with biopharma companies. This status allowed them to gain licenses for blockbusters Lipitor and Celebrex  from Parke Davis and Searle, respectively, companies which Pfizer eventually acquired. 

It will be interesting to see if Nektar finds a niche partner like Cephalon to take on Exubera sales.



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s


%d bloggers like this: